954147-35-4

Basic information

• Product Name: (S)-2-((((9H-fluoren-9-yl)Methoxy)carbonyl)aMino)-3-(2H-tetrazol-5-yl)propanoic acid
• Synonyms: (S)-2-((((9H-fluoren-9-yl)Methoxy)carbonyl)aMino)-3-(2H-tetrazol-5-yl)propanoic acid;(alphaS)-alpha-[[(9H-Fluoren-9-ylmethoxy)carbonyl]amino]-2H-tetrazole-5-propanoic acid;S-2-Fmoc-amino-3-(1H-tetrazole-5-yl)propanoic acid;(S)-2-(FMOC-AMINO)-3-(2H-TETRAZOL-5-YL)PROPANOIC ACID
• CAS NO: 954147-35-4
• Molecular Formula: C₁₉H₁₇N₅O₄
• Molecular Weight: 379.36938
• Mol File: 954147-35-4.mol

Chemical Properties

• Melting Point: 202℃
• Appearance: /
• Density: 1.451
• Storage Temp.: 2-8°C
• PKA: 3.08±0.10(Predicted)
• CAS DataBase Reference: (S)-2-((((9H-fluoren-9-yl)Methoxy)carbonyl)aMino)-3-(2H-tetrazol-5-yl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-((((9H-fluoren-9-yl)Methoxy)carbonyl)aMino)-3-(2H-tetrazol-5-yl)propanoic acid(954147-35-4)
• EPA Substance Registry System: (S)-2-((((9H-fluoren-9-yl)Methoxy)carbonyl)aMino)-3-(2H-tetrazol-5-yl)propanoic acid(954147-35-4)

Safety Data

• Hazardous Substances Data: 954147-35-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Fmoc-L-Asn(Trt)-OH is used as a building block in peptide synthesis for the development of new drugs. Its incorporation into peptide chains allows for the modification of their properties, enhancing their stability and therapeutic potential.
Used in Organic Synthesis:
In the field of organic synthesis, Fmoc-L-Asn(Trt)-OH serves as a key intermediate, enabling the synthesis of complex organic compounds with diverse applications.
Used in Drug Delivery Systems:
Fmoc-L-Asn(Trt)-OH has been studied for its potential as a targeting ligand in drug delivery systems, allowing for the specific delivery of therapeutic agents to target cells or tissues, improving the efficacy and reducing side effects of treatments.
Used in Enzyme Inhibition:
Fmoc-L-Asn(Trt)-OH has also been investigated for its potential as an enzyme inhibitor, offering a new approach to treating diseases by modulating enzyme activity and interfering with disease pathways.

Upstream product

• 127273-06-7 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-cyanopropanoic acid 
• 71989-16-7 Fmoc-Asn-OH 

Downstream Products

• 1446478-15-4 (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(2-trityl-2H-tetrazol-5-yl)propanoic acid 

Relevant articles and documents

GLP RECEPTOR AGONISTS

The disclosures herein relate to novel compounds of formula (1 ): and salts thereof, wherein Q, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, R1, R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.

ORAL GLP RECEPTOR AGONISTS

The disclosures herein relate to novel compounds of formula (1a) or formula (1b): and salts thereof, wherein S, T, W, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, AA10, AA11, AA12, AA13, AA14, AA15, A16, AA17, AA18, AA19, AA20, AA21, AA22, Sa, Ta, Wa, Xa, Ya, Za, AA1a, AA2a, AA3a, AA4a, AA 5a, AA 6a,AA 7a,AA8a,AA 9a,AA 10a,AA11a,AA 12a,AA13aAA 14a,AA15a,AA 16a, R, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.

Tetrazole analogues of aspartic, glutamic and α-aminoadipic acids and their derivatives with tetrazole ring in side chains useful for solid-phase peptide synthesis

Tetrazole analogues of Fmoc-aspartic, -glutamic and -α-aminoadipic acids with acidic tetrazolyl group in side chains suitable for solid-phase peptide synthesis were obtained. Moreover, the appropriate derivatives of aspartic and glutamic acids containing tetrazole ring methylated in position N1 or N2 were synthesized as well.

Synthesis of tetrazole analogues of amino acids using Fmoc chemistry: isolation of amino free tetrazoles and their incorporation into peptides

An efficient synthesis of tetrazole analogues of amino acids starting from Nα-Fmoc amino acid in a three-step protocol is reported. The free amino tetrazoles were obtained in good yields and with excellent purity after removal of the Fmoc group